Saturday, May 28, 2011

A map of Canada exhibiting its ten provinces a...Image via Wikipedia
Audio copy of the 2011 MS Research Teleconference now available!
On May 11, 2011, the MS Society of Canada hosted the annual MS Research Teleconference. This year, Dr. Paul O’Connor discussed the latest in MS research including CCSVI and took questions from callers.  to download MP3 click on this link http://mssociety.ca/en/research/default.htmhttp://mssociety.ca/en/research/default.htm

Bookmark and Share
Enhanced by Zemanta

Friday, May 20, 2011

MS Patients Show Relapse Rate Reduction in Coptimize Study
Drug Discovery & Development - May 19, 2011


Teva Pharmaceutical reported preliminary data from two studies, Coptimize and QualiCop.
The global Coptimize study, which followed 688 patients from 19 countries, demonstrated that patients who switched to Copaxone from other approved disease modifying therapies experienced a significant reduction of 61% in ARR.
Switching to Copaxone treatment also halted the progression of disability of patients in the trial. A majority of patients reported better overall well being and less adverse events after switching to Copaxone.
 The QualiCop study indicated a significant improvement of cognitive function and depressive symptoms over 24 months. Patients on Copaxone experienced improved overall multiple sclerosis functional composite (MSFC) scores; the MSFC measures leg function/ambulation, arm/hand function and cognitive function. The study followed 734 patients who were either treatment naive or previously-treated with other approved injectable and infused disease modifying therapies for relapsing-remitting multiple sclerosis. In both studies, patients treated with Copaxone also demonstrated stable EDSS (no disease progression) during the study periods.
The Coptimize study is an international, non-interventional, longitudinal study, recruiting relapsing-remitting multiple sclerosis (RRMS) patients switching to Copaxone from other injectable and infused disease modifying therapies approved for RRMS within three to six months of screening.



Bookmark and Share
Enhanced by Zemanta
viagra is a commercial produced medicine conta...Image via Wikipedia
Viagra may help with MS | Health & Fitness | Life | Toronto Sun
First posted:
Spanish researchers hope to soon carry out clinical trials with humans after they found mice with multiple sclerosis that were given Viagra experienced a drastic reduction in symptoms.
The researchers at the Universitat Autònoma de Barcelona found complete recovery from MS symptoms occurred in 50% of the mice after just eight days of treatment.
Multiple sclerosis is the most common chronic inflammatory disease of the central nervous system and one of the main causes of disability among young adults. There is no cure for the disease, although some drugs have proven effective in fighting symptoms and preventing it from progressing.
The study, released Thursday, was published in the journal Acta Neuropathologica. The researchers are confident clinical trials will start soon because the drug sildenafil -- which is sold as Viagra -- is already used to treat sexual dysfunction in some MS patients.

Bookmark and Share
Enhanced by Zemanta

Thursday, May 5, 2011

"May is MS Awareness Month. If you or someone you know lives with multiple sclerosis, the MS Society is here to help. mssociety.ca "



Bookmark and Share